Warnyta Minnaard
If the practitioner doesn’t know where the primary tumor is located, they cannot offer a targeted treatment plan, and nor can they give the patient an estimate of their life expectancy.
Back to newsMore news
Oncoanalyser 3.0 for cancer genomics is out, now supporting Illumina, Ultima Genomics & Roche platforms
Extensive work on the underlying WiGiTS tools now enable users to analyze sequencing data from three sequencing platforms (Illumina, Ultima …
The starting point – always the patient
Frank van Wijck, science journalist Ele Visser is handing over his position as chairman of Hartwig Medical Foundation’s Data Access Board …
Collaboration for future-proof diagnostics and to accelerate research
Complete analysis of the DNA of children with cancer offers many possibilities. It maps out all possible targeted treatment options …
By using WGS, we took a step forward in molecular diagnostics in our department from the analysis of less than 100 genes to approximately 20,000 genes per patient. This provides an enormous amount of valuable information, not only for the patient of today, but also for the patient of the future.